ABCC2抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 20 μg, Lane: Human rectum tissue lysate, Primary antibody: P06901(ABCC2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 40 seconds    

  
  

The ABCC2 antibody targets the ATP-binding cassette (ABC) transporter subfamily C member 2 (ABCC2), also known as Multidrug Resistance-Associated Protein 2 (MRP2). ABCC2 is a membrane-bound efflux transporter expressed predominantly in the liver, kidneys, and intestines. It plays a critical role in the excretion of organic anions, including conjugated bilirubin, glutathione, and drug metabolites, into bile or urine. ABCC2 dysfunction is linked to Dubin-Johnson syndrome, a hereditary disorder characterized by chronic conjugated hyperbilirubinemia. In cancer, ABCC2 overexpression is associated with multidrug resistance (MDR) by mediating the efflux of chemotherapeutic agents, reducing their intracellular efficacy.

The ABCC2 antibody is widely used in research to study the protein’s expression, localization, and function in normal physiology and disease. It is developed using immunogens such as recombinant ABCC2 protein fragments or synthetic peptides corresponding to specific epitopes, often validated in models like Western blotting, immunohistochemistry, or immunofluorescence. Researchers employ this antibody to investigate ABCC2's role in drug transport, detoxification pathways, and its impact on pharmacokinetics. Additionally, it aids in exploring mechanisms underlying liver/kidney diseases, drug-induced toxicity, and chemoresistance in oncology. Reliable ABCC2 antibodies are essential for advancing therapeutic strategies targeting ABC transporters.